Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors
Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors(773 views) Vitale RM, Alterio V, Innocenti A, Winum JY, Monti SM, De Simone G, Supuran CT
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2009 Oct 8; 52(19): 5990-5998.
Keywords: Aliphatic Compound, Bis Sulfamate, Carbonate Dehydratase, Carbonate Dehydratase Inhibitor, Isoenzyme, Sulfamic Acid, Sulfonamide, Sulfonic Acid Derivative, Unclassified Drug, Article, Binding Affinity, Crystal Structure, Drug Design, Drug Structure, Antigens, Neoplasm, Carbonic Anhydrase Ii, Carbonic Anhydrase Inhibitors, Catalytic Domain, Humans, Models, Molecular, Protein Binding, Structure-Activity Relationship,
Affiliations: *** IBB - CNR ***
Istituto di Chimica Biomolecolare - CNR, Via Campi Flegrei 34, 80078, Pozzuoli, Italy
Istituto di Biostrutture e Bioimmagini - CNR, Via Mezzocannone 16, 80134 Napoli, Italy
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Via della Lastruccia 3, I-50019 Sesto Fiorentino, Firenze, Italy
Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS-UM1-UM2, Ecole Nationale Supérieure de Chimie de Montpellier, 8 Rue de l'Ecole Normale, 34296 Montpellier Cedex, France
References: Not available.
Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors
Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors
No results.
Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors